In this white paper, we discuss current challenges in the lengthy and iterative preclinical development pipeline for cell therapies and how cell avidity can improve confidence in lead candidate selection to speed up IND filings with 50% greater predictive power to in vivo outcomes compared to traditional in vitro assays such as cytokine secretion and cytotoxicity.
Learning objectives:
- Preclinical cell therapy drug development is a costly and time-consuming process, with a high failure rate in clinical trials.
- Traditional in vitro assays often yield inconclusive results, leading to limited predictive power for in vivo efficacy and a high probability of not identyfing the optimal candidate for clinical trials.
- Cell Avidity has emerged as a superior predictor of in vivo efficacy, offering an accelerated pathway towards a successful IND filing.
